Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvironments are diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups and their underlying genomic abnormalities, pathway signatures, and microenvironment compositions to uncover biomarkers and therapeutic vulnerabilities. We studied 303 SMZL spleen samples collected through the IELSG46 multicenter international study (NCT02945319) by using a multiplatform approach. We carried out genetic and phenotypic analyses, defined self-organized signatures, validated the findings in independent primary tumor metadata and in genetically modified mouse models, and determined correlations with outcome data. We identified 2 prominent genetic clusters in SMZL, termed NNK (58% of cases, harboring NF-κB, NOTCH, and KLF2 modules) and DMT (32% of cases, with DNA-damage response, MAPK, and TLR modules). Genetic aberrations in multiple genes as well as cytogenetic and immunogenetic features distinguished NNK- from DMT-SMZLs. These genetic clusters not only have distinct underpinning biology, as judged by differences in gene-expression signatures, but also different outcomes, with inferior survival in NNK-SMZLs. Digital cytometry and in situ profiling segregated 2 basic types of SMZL immune microenvironments termed immune-suppressive SMZL (50% of cases, associated with inflammatory cells and immune checkpoint activation) and immune-silent SMZL (50% of cases, associated with an immune-excluded phenotype) with distinct mutational and clinical connotations. In summary, we propose a nosology of SMZL that can implement its classification and also aid in the development of rationally targeted treatments.
Genetic and phenotypic attributes of splenic marginal zone lymphoma / Bonfiglio, F.; Bruscaggin, A.; Guidetti, F.; Terzi di Bergamo, L.; Faderl, M.; Spina, V.; Condoluci, A.; Bonomini, L.; Forestieri, G.; Koch, R.; Piffaretti, D.; Pini, K.; Pirosa, M. C.; Cittone, M. G.; Arribas, A.; Lucioni, M.; Ghilardi, G.; Wu, W.; Arcaini, L.; Baptista, M. J.; Bastidas, G.; Bea, S.; Boldorini, R.; Broccoli, A.; Buehler, M. M.; Canzonieri, V.; Cascione, L.; Ceriani, L.; Cogliatti, S.; Corradini, P.; Derenzini, E.; Devizzi, L.; Dietrich, S.; Elia, A. R.; Facchetti, F.; Gaidano, G.; Garcia, J. F.; Gerber, B.; Ghia, P.; Gomes da Silva, M.; Gritti, G.; Guidetti, A.; Hitz, F.; Inghirami, G.; Ladetto, M.; Lopez-Guillermo, A.; Lucchini, E.; Maiorana, A.; Marasca, R.; Matutes, E.; Meignin, V.; Merli, M.; Moccia, A.; Mollejo, M.; Montalban, C.; Novak, U.; Oscier, D. G.; Passamonti, F.; Piazza, F.; Pizzolitto, S.; Rambaldi, A.; Sabattini, E.; Salles, G.; Santambrogio, E.; Scarfo, L.; Stathis, A.; Stussi, G.; Geyer, J. T.; Tapia, G.; Tarella, C.; Thieblemont, C.; Tousseyn, T.; Tucci, A.; Vanini, G.; Visco, C.; Vitolo, U.; Walewska, R.; Zaja, F.; Zenz, T.; Zinzani, P. L.; Khiabanian, H.; Calcinotto, A.; Bertoni, F.; Bhagat, G.; Campo, E.; De Leval, L.; Dirnhofer, S.; Pileri, S. A.; Piris, M. A.; Traverse-Glehen, A.; Tzankov, A.; Paulli, M.; Ponzoni, M.; Mazzucchelli, L.; Cavalli, F.; Zucca, E.; Rossi, D.. - In: BLOOD. - ISSN 0006-4971. - 139:5(2022), pp. 732-747. [10.1182/blood.2021012386]
Genetic and phenotypic attributes of splenic marginal zone lymphoma
Maiorana A.;Marasca R.;
2022
Abstract
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvironments are diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups and their underlying genomic abnormalities, pathway signatures, and microenvironment compositions to uncover biomarkers and therapeutic vulnerabilities. We studied 303 SMZL spleen samples collected through the IELSG46 multicenter international study (NCT02945319) by using a multiplatform approach. We carried out genetic and phenotypic analyses, defined self-organized signatures, validated the findings in independent primary tumor metadata and in genetically modified mouse models, and determined correlations with outcome data. We identified 2 prominent genetic clusters in SMZL, termed NNK (58% of cases, harboring NF-κB, NOTCH, and KLF2 modules) and DMT (32% of cases, with DNA-damage response, MAPK, and TLR modules). Genetic aberrations in multiple genes as well as cytogenetic and immunogenetic features distinguished NNK- from DMT-SMZLs. These genetic clusters not only have distinct underpinning biology, as judged by differences in gene-expression signatures, but also different outcomes, with inferior survival in NNK-SMZLs. Digital cytometry and in situ profiling segregated 2 basic types of SMZL immune microenvironments termed immune-suppressive SMZL (50% of cases, associated with inflammatory cells and immune checkpoint activation) and immune-silent SMZL (50% of cases, associated with an immune-excluded phenotype) with distinct mutational and clinical connotations. In summary, we propose a nosology of SMZL that can implement its classification and also aid in the development of rationally targeted treatments.
| File | Dimensione | Formato | |
|---|---|---|---|
|
bloodbld2021012386.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
3.9 MB
Formato
Adobe PDF
|
3.9 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
